In this WDR5 case study, we utilized Novartis internal archived diverse library consisting of 3 to 4 million compounds. Beyond this, multiple compound sources can be utilized potentially in this pipeline including an external Enamine REAL database covering 4 to 10 billion compounds and a customized enumeration library. For all the molecules obtained from the ROCS analysis, we calculated the GBVI/WSA ΔG score and further refined the compound selection based on availability, solubility, and quality control results. This rigorous selection process resulted in a focused set of 2029 compounds for subsequent biological testing.